Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 3/20 | 0.46 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.45 |
| ▸ | XDH | P47989 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | DHODH | Q02127 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.43 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL110393 | 0.85 | DHODH (0.52) | MCL1XDHDHODHMAPTNPSR1 | |
| SCHEMBL138132 | 0.85 | PTGER1 (0.44) | MCL1SMPD1CNR1DHODH | |
| SCHEMBL15976013 | 0.83 | MCL1 (0.41) | MCL1SMPD1CNR1NPC1RAB9A | |
| SCHEMBL110248 | 0.82 | KDM4E (0.42) | CNR1RAB9AMAPTPLA2G2AMEN1 | |
| SCHEMBL109071 | 0.80 | CA12 (0.42) | NPC1RAB9ASMN1; SMN2MAPTNPSR1 | |
| SCHEMBL23958640 | 0.79 | LMNA (0.49) | NPC1RAB9ASMN1; SMN2DHODHMAPT | |
| SCHEMBL110319 | 0.79 | MAPT (0.48) | CNR1NPC1RAB9ASMN1; SMN2DHODH | |
| SCHEMBL111300 | 0.79 | ALDH1A1 (0.41) | DHODHMAPTMEN1KMT2A | |
| SCHEMBL109836 | 0.76 | ALOX5AP (0.40) | RAB9AMAPTMEN1KMT2A | |
| SCHEMBL139273 | 0.76 | MKNK1 (0.45) | MEN1PABPC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8815840-B2 | Carbazole and carboline kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-26 | — | — | US | disclosed |
| US-8815840-B2 | Carbazole and carboline kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-26 | — | — | US | disclosed |
| US-8815840-B2 | Carbazole and carboline kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-26 | — | — | US | disclosed |
| EP-2370407-B1 | CARBAZOLE AND CARBOLINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-06-18 | — | — | EP | disclosed |
| EP-2370407-B1 | CARBAZOLE AND CARBOLINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-06-18 | — | — | EP | disclosed |
| US-20120058988-A1 | CARBAZOLE AND CARBOLINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-03-08 | — | — | US | disclosed |
| US-20120058988-A1 | CARBAZOLE AND CARBOLINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-03-08 | — | — | US | disclosed |
| US-20120058988-A1 | CARBAZOLE AND CARBOLINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-03-08 | — | — | US | disclosed |
| EP-2370407-A1 | CARBAZOLE AND CARBOLINE KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2011-10-05 | — | — | EP | disclosed |
| WO-2010080474-A1 | CARBAZOLE AND CARBOLINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058988-A1 | CARBAZOLE AND CARBOLINE KINASE INHIBITORS | JAK2, JAK1, JAK3 | MCL1 36/4885SMPD1 3358/4885XDH 1318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.